# A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

> **NCT04608500** · PHASE3 · COMPLETED · sponsor: **Vyne Therapeutics Inc.** · enrollment: 771 (actual)

## Conditions studied

- Facial Papulopustular Rosacea

## Interventions

- **DRUG:** FMX103 minocycline foam 1.5%
- **DRUG:** Vehicle foam

## Key facts

- **NCT ID:** NCT04608500
- **Lead sponsor:** Vyne Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-01
- **Primary completion:** 2018-07-02
- **Final completion:** 2018-07-31
- **Target enrollment:** 771 (ACTUAL)
- **Last updated:** 2021-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608500, "A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04608500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*